tiprankstipranks
Advertisement
Advertisement

ORIC Stock Latest News

Oric Pharmaceuticals initiates Himalayas-1 trial
The FlyOric Pharmaceuticals initiates Himalayas-1 trial
4d ago
ORIC
Oric Shareholders Approve Equity Plan, Governance Measures
PremiumCompany Announcements
Oric Shareholders Approve Equity Plan, Governance Measures
26d ago
8K
ORIC
Oric Pharmaceuticals resumed with a Buy at Stifel
PremiumThe Fly
Oric Pharmaceuticals resumed with a Buy at Stifel
1M ago
ORIC
Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained
PremiumRatings
Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained
1M ago
ORIC
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
PremiumRatings
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
2M ago
ORIC
Oric Pharmaceuticals moved to Buy rating at Goldman Sachs
PremiumThe FlyOric Pharmaceuticals moved to Buy rating at Goldman Sachs
2M ago
ORIC
ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts
Premium
Ratings
ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts
2M ago
ORIC
Oric Pharmaceuticals price target lowered to $16 from $17 at Citi
Premium
The Fly
Oric Pharmaceuticals price target lowered to $16 from $17 at Citi
2M ago
ORIC
Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)
PremiumThe Fly
Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)
3M ago
ORIC
Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR
PremiumThe Fly
Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR
3M ago
ORIC
3 Best Stocks to Buy amid the Market Pullback, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy amid the Market Pullback, According to Top Analysts
4M ago
ENGN
ORIC
Oric selloff brings attractive entry point, says H.C. Wainwright
PremiumThe Fly
Oric selloff brings attractive entry point, says H.C. Wainwright
4M ago
ORIC
Oric Pharmaceuticals should be bought on selloff, says Citi
PremiumThe FlyOric Pharmaceuticals should be bought on selloff, says Citi
4M ago
ORIC
Midday Fly By: Nike falls after earnings, Conagra reports mixed results
Premium
The Fly
Midday Fly By: Nike falls after earnings, Conagra reports mixed results
4M ago
LW
RH
Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush
Premium
The Fly
Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush
4M ago
PFE
ORIC
Oric’s rinzi efficacy ‘comparable’ to Pfizer’s mevro, says Cantor Fitzgerald
PremiumThe Fly
Oric’s rinzi efficacy ‘comparable’ to Pfizer’s mevro, says Cantor Fitzgerald
4M ago
PFE
ORIC
Oric selloff on cancer data ‘appears exaggerated,’ says JonesResearch
PremiumThe Fly
Oric selloff on cancer data ‘appears exaggerated,’ says JonesResearch
4M ago
ORIC
Video: Nike stumbles as timeline for recovery pushed out
PremiumThe Fly
Video: Nike stumbles as timeline for recovery pushed out
4M ago
RH
TH
Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3
PremiumCompany Announcements
Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3
4M ago
8K
ORIC
Closing Bell Movers: Nike slides 9% after Q3 results, soft outlook
PremiumThe FlyClosing Bell Movers: Nike slides 9% after Q3 results, soft outlook
4M ago
RH
NKE
Oric Pharmaceuticals announces rinzimetostat, ORIC-944, program update
Premium
The Fly
Oric Pharmaceuticals announces rinzimetostat, ORIC-944, program update
4M ago
ORIC
Oric selloff brings favorable entry point, says H.C. Wainwright
Premium
The Fly
Oric selloff brings favorable entry point, says H.C. Wainwright
4M ago
ORIC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >